Balancing EU Setback and Pipeline Optionality: Justifying a Hold on ACADIA

ACADIA Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterated a Hold rating on the stock and has a $29.00 price target.

Tazeen Ahmad has given his Hold rating due to a combination of factors related to both opportunity and uncertainty in ACADIA’s outlook. The negative CHMP view on trofinetide in Rett syndrome materially reduces visibility on a near-term EU approval, leading her to cut the probability of European success, push back the assumed launch to 2027, and trim the contribution from Daybue in her valuation, even though U.S. guidance for 2026 Daybue sales remains intact.

At the same time, she recognizes that trofinetide is already approved in the U.S. and continues to generate EU revenue through a named patient program, while a re-examination by CHMP still offers a modest 20–30% chance of overturning the decision. She also sees pipeline optionality from remlifanserin in Alzheimer’s disease psychosis, where physicians are seeking safer on-label options, but believes the overall risk–reward profile, pending key data and regulatory outcomes, supports maintaining a Neutral stance rather than a more decisive Buy or Sell view.

Ahmad covers the Healthcare sector, focusing on stocks such as Argenx Se, Gilead Sciences, and Regeneron. According to TipRanks, Ahmad has an average return of 1.7% and a 53.70% success rate on recommended stocks.

In another report released on February 26, Stifel Nicolaus also maintained a Hold rating on the stock with a $24.00 price target.